1- Tiwari N, Baldwin. DS. Yogic breathing techniques in the management of anxiety and depression: systematic review of evidence of efficacy and presumed mechanism of action. Anxiety 2018; 3:220-8.
2- Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch General Psychiatry 2005; 62:617-27.
3- Gottlieb SS, Kop WJ, Thomas SA, Katzen S, Vesely MR, Greenberg N, et al. A double-blind placebo-controlled pilot study of controlled-release paroxetine on depression and quality of life in chronic heart failure. Am Heart J 2007; 153:868-73.
4- Hoff LA, Morgan BD. Psychiatric and mental health essentials in primary care. Abingdon: Routledge; 2010.
5- Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011; 21:718-79.
6- Martinez‐Martin P, Rojo‐Abuin JM, Dujardin K, Pontone GM, Weintraub D, Forjaz MJ, et al. Designing a new scale to measure anxiety symptoms in Parkinson's disease: item selection based on canonical correlation analysis. Eur J Neurol 2013; 20:1198-203.
7- Allen F, Fisher M, Phipps N. The correlation between depression and diabetes. US Pharma 2014; 39:12-5.
8- Stefanova E, Ziropadja L, Petrović M, Stojković T, Kostić V. Screening for anxiety symptoms in Parkinson disease: a cross-sectional study. J Geriatric Psychiatry Neurol 2013; 26:34-40.
9- Dozeman E, van Schaik DJ, van Marwijk HW, Stek ML, Beekman AT, van der Horst HE. Feasibility and effectiveness of activity-scheduling as a guided self-help intervention for the prevention of depression and anxiety in residents in homes for the elderly: a pragmatic randomized controlled trial. Int Psychogeriatr 2011; 23:969-78.
10- Spence SH, Rapee RM. The etiology of social anxiety disorder: an evidence-based model. Behav Res Ther 2016; 86:50-67.
11- Kishi T, Matsuda Y, Matsunaga S, Moriwaki M, Otake Y, Akamatsu K, et al. Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial. Neuropsychiatr Dis Treat 2017; 13:117.
12- Otsubo T, Watanabe Y, Hongo S, Inoue M, Akimoto K, Murakami K, et al. Comparative effectiveness of switching paroxetine formulation for treatment of major depressive disorder: an open-label multicenter study. Neuropsychiatr Dis Treat 2018; 14:955.
13- Kubzansky LD, Kawachi I. Going to the heart of the matter: do negative emotions cause coronary heart disease? J Psychosomatic Res 2000; 48:323-37.
14- Sugarman MA, Loree AM, Baltes BB, Grekin ER, Kirsch I. The efficacy of paroxetine and placebo in treating anxiety and depression: a meta-analysis of change on the Hamilton Rating Scales. PloS One 2014; 9:e106337.
15- Harmer D, Phil CJ, O’Sullivan U, Favaron E, Massey-Chase R, Ayres R, et al. Effect of acute antidepressant administration on negative affective bias in depressed patients. Am J Psychiatry 2009; 166:1178-84.
16- Rickels K, Zaninelli R, McCafferty J, Bellew K, Iyengar M, Sheehan D. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2003; 160:749-56.
17- Wagner KD, Berard R, Stein MB, Wetherhold E, Carpenter DJ, Perera P, et al. A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch General Psychiatry 2004; 61:1153-62.
18- Olfson M, Kroenke K, Wang S, Blanco C. Trends in office-based mental health care provided by psychiatrists and primary care physicians. J Clin Psychiatry 2014; 75:247-53.